Characterization of Transcriptional Changes in ERG Rearrangement-Positive Prostate Cancer Identifies the Regulation of Metabolic Sensors Such as Neuropeptide Y

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Massoner, Petra ^a,b   Kugler, Karl G ^c   Unterberger, Karin ^b   Kuner, Ruprecht ^d   Mueller, Laurin A J ^c   Fälth, Maria ^d   Schäfer, Georg ^a   Seifarth, Christof ^a   Ecker, Simone ^c   Verdorfer, Irmgard ^a   Graber, Armin ^c   Sültmann, Holger ^d   Klocker, Helmut ^a,b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Center for Personalized Cancer Medicine GmbH   (Austria)

^c UNIVERSITY FOR HEALTH SCIENCES   (Austria)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; MESSENGER RNA; NEUROPEPTIDE Y;

ADULT; ARTICLE; AZGP1 GENE; CELL METABOLISM; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE; GENE CLUSTER; GENE EXPRESSION; GENE FUNCTION; GENE REARRANGEMENT; GENETIC ASSOCIATION; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; MICROARRAY ANALYSIS; NEUROPEPTIDE Y GENE; NUCLEOTIDE SEQUENCE; ONCOGENE; PLA2G7 GENE; PROSTATE CANCER; PROTEIN ANALYSIS; TFF3 GENE; TRANSCRIPTION REGULATION; V ETS ERYTHROBLASTOSIS VIRUS E26 ONCOGENE HOMOLOG GENE; VALIDATION STUDY;

AGED; BIOLOGICAL TRANSPORT; CARRIER PROTEINS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE; GLYCOPROTEINS; HUMANS; MALE; MIDDLE AGED; NEUROPEPTIDE Y; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PEPTIDES; PHOSPHOLIPASES A2; PROSTATIC NEOPLASMS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC;

EID: 84873499110     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055207     Document Type: Article

References (75)

1. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, et al. (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644-648.
2. Han B, Mehra R, Dhanasekaran SM, Yu J, Menon A, et al. (2008) A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res 68: 7629-7637.
3. Tomlins SA, Bjartell A, Chinnaiyan AM, Jenster G, Nam RK, et al. (2009) ETS Gene Fusions in Prostate Cancer: From Discovery to Daily Clinical Practice. Eur Urol.
4. Mehra R, Tomlins SA, Yu J, Cao X, Wang L, et al. (2008) Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res 68: 3584-3590.
5. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, et al. (2007) Integrative molecular concept modeling of prostate cancer progression. Nat Genet 39: 41-51.
6. Helgeson BE, Tomlins SA, Shah N, Laxman B, Cao Q, et al. (2008) Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res 68: 73-80.
7. Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, et al. (2009) Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 69: 2912-2918.
8. Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, et al. (2007) Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448: 595-599.
9. Klezovitch O, Risk M, Coleman I, Lucas JM, Null M, et al. (2008) A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci U S A 105: 2105-2110.
10. Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, et al. (2008) Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10: 177-188.
11. Wang J, Cai Y, Yu W, Ren C, Spencer DM, et al. (2008) Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Res 68: 8516-8524.
12. Mehra R, Tomlins SA, Shen R, Nadeem O, Wang L, et al. (2007) Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 20: 538-544.
13. Nam RK, Sugar L, Yang W, Srivastava S, Klotz LH, et al. (2007) Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer 97: 1690-1695.
14. Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, et al. (2008) Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 27: 253-263.
15. Lapointe J, Kim YH, Miller MA, Li C, Kaygusuz G, et al. (2007) A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Mod Pathol 20: 467-473.
16. Tu JJ, Rohan S, Kao J, Kitabayashi N, Mathew S, et al. (2007) Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Mod Pathol 20: 921-928.
17. Gopalan A, Leversha MA, Satagopan JM, Zhou Q, Al-Ahmadie HA, et al. (2009) TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res 69: 1400-1406.
18. Saramaki OR, Harjula AE, Martikainen PM, Vessella RL, Tammela TL, et al. (2008) TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res 14: 3395-3400.
19. Boormans JL, Porkka K, Visakorpi T, Trapman J, (2011) Confirmation of the association of TMPRSS2(exon 0):ERG expression and a favorable prognosis of primary prostate cancer. Eur Urol 60: 183-184.
20. Schena M, Shalon D, Davis RW, Brown PO, (1995) Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270: 467-470.
21. Bartsch G, Horninger W, Klocker H, Pelzer A, Bektic J, et al. (2008) Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. BJU Int 101: 809-816.
22. Edgar R, Domrachev M, Lash AE, (2002) Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30: 207-210.
23. Parkinson H, Sarkans U, Kolesnikov N, Abeygunawardena N, Burdett T, et al. (2011) ArrayExpress update-an archive of microarray and high-throughput sequencing-based functional genomics experiments. Nucleic Acids Res 39: D1002-1004.
24. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, et al. (2004) ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6: 1-6.
25. Wu Z, Irizarry RA, (2005) Stochastic models inspired by hybridization theory for short oligonucleotide arrays. J Comput Biol 12: 882-893.
26. Wu Z, Irizarry R, Gentleman R, Martinez-Murillo F, Spencer F, (2004) GCRMA A Model-Based Background Adjustment for Oligonucleotide Expression Arrays. Journal of the American Statistical Association 99: 909.
27. Rhodes DR, Barrette TR, Rubin MA, Ghosh D, Chinnaiyan AM, (2002) Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res 62: 4427-4433.
28. Romualdi C, De Pitta C, Tombolan L, Bortoluzzi S, Sartori F, et al. (2006) Defining the gene expression signature of rhabdomyosarcoma by meta-analysis. BMC Genomics 7: 287.
29. Durinck S, Moreau Y, Kasprzyk A, Davis S, De Moor B, et al. (2005) BioMart and Bioconductor: a powerful link between biological databases and microarray data analysis. Bioinformatics 21: 3439-3440.
30. Fisher RA (1925) Statistical Methods for Research Workers. Edinburgh: Oliver & Boyd.
31. Moreau Y, Aerts S, De Moor B, De Strooper B, Dabrowski M, (2003) Comparison and meta-analysis of microarray data: from the bench to the computer desk. Trends Genet 19: 570-577.
32. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, et al. (2003) DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4: P3.
33. Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, et al. (2006) TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 66: 8337-8341.
34. Du P, Kibbe WA, Lin SM, (2008) lumi: a pipeline for processing Illumina microarray. Bioinformatics 24: 1547-1548.
35. Smyth GK, (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article3.
36. Kuner R, Falth M, Pressinotti NC, Brase JC, Puig SB, et al. (2012) The maternal embryonic leucine zipper kinase (MELK) is upregulated in high-grade prostate cancer. J Mol Med (Berl).
37. Kogan I, Goldfinger N, Milyavsky M, Cohen M, Shats I, et al. (2006) hTERT-immortalized prostate epithelial and stromal-derived cells: an authentic in vitro model for differentiation and carcinogenesis. Cancer Res 66: 3531-3540.
38. Bello D, Webber MM, Kleinman HK, Wartinger DD, Rhim JS, (1997) Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis 18: 1215-1223.
39. Paland N, Kamer I, Kogan-Sakin I, Madar S, Goldfinger N, et al. (2009) Differential influence of normal and cancer-associated fibroblasts on the growth of human epithelial cells in an in vitro cocultivation model of prostate cancer. Mol Cancer Res 7: 1212-1223.
40. Massoner P, Ladurner Rennau M, Heidegger I, Kloss-Brandstatter A, Summerer M, et al. (2011) Expression of the IGF axis is decreased in local prostate cancer but enhanced after benign prostate epithelial differentiation and TGF-beta treatment. Am J Pathol 179: 2905-2919.
41. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5: R80.
42. Kugler KG, Mueller LA, Graber A, (2010) MADAM- An open source meta-analysis toolbox for R and Bioconductor. Source Code Biol Med 5: 3.
43. Jiang Z, Woda BA, Wu CL, Yang XJ, (2004) Discovery and clinical application of a novel prostate cancer marker: alpha-methylacyl CoA racemase (P504S). Am J Clin Pathol 122: 275-289.
44. Bu H, Bormann S, Schafer G, Horninger W, Massoner P, et al. (2010) The anterior gradient 2 (AGR2) gene is overexpressed in prostate cancer and may be useful as a urine sediment marker for prostate cancer detection. Prostate.
45. Kosari F, Asmann YW, Cheville JC, Vasmatzis G, (2002) Cysteine-rich secretory protein-3: a potential biomarker for prostate cancer. Cancer Epidemiol Biomarkers Prev 11: 1419-1426.
46. Magee JA, Araki T, Patil S, Ehrig T, True L, et al. (2001) Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res 61: 5692-5696.
47. Ramachandran S, Liu P, Young AN, Yin-Goen Q, Lim SD, et al. (2005) Loss of HOXC6 expression induces apoptosis in prostate cancer cells. Oncogene 24: 188-198.
48. Ashida S, Nakagawa H, Katagiri T, Furihata M, Iiizumi M, et al. (2004) Molecular features of the transition from prostatic intraepithelial neoplasia (PIN) to prostate cancer: genome-wide gene-expression profiles of prostate cancers and PINs. Cancer Res 64: 5963-5972.
49. Brase JC, Johannes M, Mannsperger H, Falth M, Metzger J, et al. (2011) TMPRSS2-ERG-specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-beta signaling. BMC Cancer 11: 507.
50. Park K, Tomlins SA, Mudaliar KM, Chiu YL, Esgueva R, et al. (2010) Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 12: 590-598.
51. Rickman DS, Chen YB, Banerjee S, Pan Y, Yu J, et al. (2010) ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression. Neoplasia 12: 1031-1040.
52. Vainio P, Gupta S, Ketola K, Mirtti T, Mpindi JP, et al. (2011) Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer. Am J Pathol 178: 525-536.
53. Zhang L, Bijker MS, Herzog H, (2011) The neuropeptide Y system: pathophysiological and therapeutic implications in obesity and cancer. Pharmacol Ther 131: 91-113.
54. Walther C, Morl K, Beck-Sickinger AG, (2011) Neuropeptide Y receptors: ligand binding and trafficking suggest novel approaches in drug development. J Pept Sci 17: 233-246.
55. Bondar OP, Barnidge DR, Klee EW, Davis BJ, Klee GG, (2007) LC-MS/MS quantification of Zn-alpha2 glycoprotein: a potential serum biomarker for prostate cancer. Clin Chem 53: 673-678.
56. Descazeaud A, de la Taille A, Allory Y, Faucon H, Salomon L, et al. (2006) Characterization of ZAG protein expression in prostate cancer using a semi-automated microscope system. Prostate 66: 1037-1043.
57. Zhang SX, Bentel JM, Ricciardelli C, Horsfall DJ, Haagensen DE, et al. (1998) Immunolocalization of apolipoprotein D, androgen receptor and prostate specific antigen in early stage prostate cancers. J Urol 159: 548-554.
58. Rodriguez JC, Diaz M, Gonzalez LO, Sanchez J, Sanchez MT, et al. (2000) Apolipoprotein D expression in benign and malignant prostate tissues. Int J Surg Investig 2: 319-326.
59. Rasiah KK, Kench JG, Gardiner-Garden M, Biankin AV, Golovsky D, et al. (2006) Aberrant neuropeptide Y and macrophage inhibitory cytokine-1 expression are early events in prostate cancer development and are associated with poor prognosis. Cancer Epidemiol Biomarkers Prev 15: 711-716.
60. Vestergaard EM, Borre M, Poulsen SS, Nexo E, Torring N, (2006) Plasma levels of trefoil factors are increased in patients with advanced prostate cancer. Clin Cancer Res 12: 807-812.
61. Ruscica M, Dozio E, Boghossian S, Bovo G, Martos Riano V, et al. (2006) Activation of the Y1 receptor by neuropeptide Y regulates the growth of prostate cancer cells. Endocrinology 147: 1466-1473.
62. Nagakawa O, Ogasawara M, Murata J, Fuse H, Saiki I, (2001) Effect of prostatic neuropeptides on migration of prostate cancer cell lines. Int J Urol 8: 65-70.
63. Nagakawa O, Ogasawara M, Fujii H, Murakami K, Murata J, et al. (1998) Effect of prostatic neuropeptides on invasion and migration of PC-3 prostate cancer cells. Cancer Lett 133: 27-33.
64. Shi YC, Baldock PA, (2012) Central and peripheral mechanisms of the NPY system in the regulation of bone and adipose tissue. Bone 50: 430-436.
65. Hirsch D, Zukowska Z, (2012) NPY and stress 30 years later: the peripheral view. Cell Mol Neurobiol 32: 645-659.
66. Suva LJ, Washam C, Nicholas RW, Griffin RJ, (2011) Bone metastasis: mechanisms and therapeutic opportunities. Nat Rev Endocrinol 7: 208-218.
67. Cheville JC, Karnes RJ, Therneau TM, Kosari F, Munz JM, et al. (2008) Gene panel model predictive of outcome in men at high-risk of systemic progression and death from prostate cancer after radical retropubic prostatectomy. J Clin Oncol 26: 3930-3936.
68. Bermudo R, Abia D, Ferrer B, Nayach I, Benguria A, et al. (2008) Co-regulation analysis of closely linked genes identifies a highly recurrent gain on chromosome 17q25.3 in prostate cancer. BMC Cancer 8: 315.
69. Chandran UR, Ma C, Dhir R, Bisceglia M, Lyons-Weiler M, et al. (2007) Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer 7: 64.
70. Liu P, Ramachandran S, Ali Seyed M, Scharer CD, Laycock N, et al. (2006) Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. Cancer Res 66: 4011-4019.
71. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, et al. (2002) Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 1: 203-209.
72. Tsavachidou D, McDonnell TJ, Wen S, Wang X, Vakar-Lopez F, et al. (2009) Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst 101: 306-320.
73. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, et al. (2005) Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8: 393-406.
74. Wallace TA, Prueitt RL, Yi M, Howe TM, Gillespie JW, et al. (2008) Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res 68: 927-936.
75. Wang Y, Xia XQ, Jia Z, Sawyers A, Yao H, et al. (2010) In silico estimates of tissue components in surgical samples based on expression profiling data. Cancer Res 70: 6448-6455.